Core Insights - BioSyent Inc. reported strong financial results for Q4 and FY 2025, with total company revenue growth of 23% year-over-year, driven by both Canadian and international pharmaceutical sales [1][2]. Financial Performance - Q4 2025 Canadian Pharma Sales reached CAD 8,792,653, a 3% increase from Q4 2024, while FY 2025 Canadian Pharma Sales totaled CAD 37,143,783, reflecting a 13% increase from FY 2024 [1]. - International Pharma Sales surged to CAD 601,387 in Q4 2025, marking a 240% increase year-over-year, and FY 2025 International Pharma Sales reached CAD 3,735,959, up 302% from FY 2024 [1]. - Legacy Business Sales saw a significant rise, with Q4 2025 sales of CAD 277,883, up 278%, and FY 2025 sales of CAD 2,172,241, an 86% increase [1]. - Total Company Sales for Q4 2025 were CAD 9,671,923, a 10% increase, and for FY 2025, total sales were CAD 43,051,983, a 23% increase [1]. - EBITDA for Q4 2025 was CAD 2,528,561, up 13%, and for FY 2025, it was CAD 12,122,756, reflecting a 30% increase [1][6]. - Net Income After Taxes (NIAT) for Q4 2025 was CAD 1,991,788, a 23% increase, and for FY 2025, it was CAD 9,012,232, up 24% [1][6]. Strategic Initiatives - The company continues to invest in its key products, including FeraMAX and Tibella/Tibelia, which have been significant revenue drivers [2]. - BioSyent has maintained a healthy NIAT margin of 21% for FY 2025 and has a track record of 62 consecutive profitable quarters [2]. - The company completed the acquisition of Oral Science Inc., expanding its portfolio in the oral health sector [4]. Shareholder Returns - BioSyent repurchased 19,500 common shares under a Normal Course Issuer Bid (NCIB) during FY 2025 and increased its quarterly dividend by 10% to CAD 0.055 per common share, paid on March 13, 2026 [4].